Law360, New York (January 06, 2012, 7:50 PM ET) -- Canadian drugmaker Valeant Pharmaceuticals International Inc. is threatening to walk away from its hostile $327 million bid for California-based Ista Pharmaceuticals Inc. unless a deal is struck by the end of the month, according to a Friday regulatory filing.
In hopes of merging Valeant's small ophthalmology operation with Ista's prominent eye care business, Canada's largest drugmaker has proposed a buyout of $6.50 per share, which is a 68 percent premium over a 60-day volume weighted trading average of $3.87 per share, according to investor documents....
Drugmaker Valeant Losing Patience In $327M Hostile Bid
To view the full article, take a free trial now.
